Artivion SVP Stanton sells $442k in company stock

Published 18/06/2025, 17:00
Artivion SVP Stanton sells $442k in company stock

Artivion, INC. (NYSE:AORT) Senior Vice President, Clinical & MD Affair, Marshall S. Stanton, sold 15,000 shares of company stock on June 17, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $29.50, for a total transaction value of $442500.

The sales involved 13,764 shares and 1236 shares. Following the transactions, Stanton directly owns 64,200 shares of Artivion, INC.

The sale was executed under a pre-arranged 10b5-1 trading plan adopted on March 14, 2025.

In other recent news, Artivion Inc. reported first-quarter 2025 earnings that exceeded Wall Street expectations, with sales reaching $99 million against a consensus of $95 million. This growth was largely driven by the early success of the AMDS product, contributing to a 19% year-over-year increase in the aortic stent graft business. However, the company’s tissue processing business experienced a 23% decline due to supply chain issues from a previous cybersecurity incident. Analysts from JMP Securities and Stifel maintained positive ratings for Artivion, with price targets set at $33 and $30, respectively, highlighting continued optimism in the company’s growth prospects.

Additionally, Artivion’s shareholders approved executive compensation and additional equity funding at the recent annual meeting. The company also announced a private deal to exchange approximately $95 million of its convertible senior notes for common stock, aiming to manage its debt effectively. Canaccord Genuity initiated coverage of Artivion with a buy rating, citing strategic investments in aortic arch repair as a key factor. The launch of new products like the Ascyrus AMDS and anticipated approvals for Endospan’s NEXUS and JOTEC’s Arcevo are expected to drive future growth. These developments reflect Artivion’s strategic focus on expanding its market presence and addressing supply chain challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.